Barclays Maintains Overweight on Merck & Co, Raises Price Target to $135
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Carter Gould has maintained an Overweight rating on Merck & Co (NYSE:MRK) and increased the price target from $130 to $135, indicating a positive outlook on the company's stock.
January 23, 2024 | 1:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Barclays has reaffirmed its Overweight rating on Merck & Co and raised the price target from $130 to $135, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst like Carter Gould from Barclays is a strong signal to the market, often leading to increased investor confidence and a potential short-term rise in the stock's price. The Overweight rating further supports the positive outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100